(Q39236976)

10 September 2017

Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands (English)

1 reference

10 September 2017

1 reference

1 reference

Paul J Dyson

4

0 references

author name string

Kelly J Kilpin

series ordinal

1

1 reference

10 September 2017

Shona M Cammack

series ordinal

2

1 reference

10 September 2017

Catherine M Clavel

series ordinal

3

1 reference

10 September 2017

language of work or name

English

0 references

publication date

1 February 2013

1 reference

10 September 2017

1 reference

10 September 2017

42

1 reference

10 September 2017

6

1 reference

10 September 2017

2008-2014

1 reference

Organometallic anticancer compounds

10 September 2017

1 reference

https://api.crossref.org/works/10.1039%2FC2DT32333H

Metal-based antitumour drugs in the post-genomic era: what comes next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2DT32333H

The status of platinum anticancer drugs in the clinic and in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2DT32333H

Targeted and multifunctional arene ruthenium chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2DT32333H

Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2DT32333H

In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2DT32333H

Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2DT32333H

Use of perfluorinated phosphines to provide thermomorphic anticancer complexes for heat-based tumor targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2DT32333H

Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2DT32333H

Targeting the DNA-topoisomerase complex in a double-strike approach with a topoisomerase inhibiting moiety and covalent DNA binder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2DT32333H

Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2DT32333H

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2DT32333H

Pharmacologically active compounds in the environment and their chirality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2DT32333H

Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2DT32333H

{(1R,2R,4R)-4-methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): a novel enantiomerically pure oxaliplatin derivative showing improved anticancer activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2DT32333H

Anticancer activity of methyl-substituted oxaliplatin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2DT32333H

Arene ruthenium(II) complexes formed by dehydrogenation of cyclohexadienes with ruthenium(III) trichloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2DT32333H

Anthracene-tethered ruthenium(II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC2DT32333H

21 January 2018

Identifiers

DOI

10.1039/C2DT32333H

1 reference

10 September 2017

1 reference